[go: up one dir, main page]

PE20081734A1 - Comprimido que comprende 2-[[6-[(3r)-3-amino-1-piperidinil]-3,4-dihidro-3-metil-2,4-dioxo-1(2h)-pirimidinil]metil]-benzonitrilo y celulosa microcristalina - Google Patents

Comprimido que comprende 2-[[6-[(3r)-3-amino-1-piperidinil]-3,4-dihidro-3-metil-2,4-dioxo-1(2h)-pirimidinil]metil]-benzonitrilo y celulosa microcristalina

Info

Publication number
PE20081734A1
PE20081734A1 PE2008000219A PE2008000219A PE20081734A1 PE 20081734 A1 PE20081734 A1 PE 20081734A1 PE 2008000219 A PE2008000219 A PE 2008000219A PE 2008000219 A PE2008000219 A PE 2008000219A PE 20081734 A1 PE20081734 A1 PE 20081734A1
Authority
PE
Peru
Prior art keywords
methyl
tablet
microcrystalline cellulose
benzonitrile
dioxo
Prior art date
Application number
PE2008000219A
Other languages
English (en)
Inventor
Akihiko Ono
Shigeyuki Marunaka
Makoto Fukuta
Original Assignee
Takeda Pharmaceutical
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39156227&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20081734(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Takeda Pharmaceutical filed Critical Takeda Pharmaceutical
Publication of PE20081734A1 publication Critical patent/PE20081734A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

SE REFIERE A UN COMPRIMIDO QUE COMPRENDE: A) UN GRANULO QUE COMPRENDE 2-[[6-[(3R)-3-AMINO-1-PIPERIDINIL]-3,4-DIHIDRO-3-METIL-2,4-DIOXO-1(2H)-PIRIMIDINIL]METIL]-BENZONITRILO Y CELULOSA MICROCRISTALINA EN UN 5-40% EN PESO; B) UN AUXILIAR DE COMPRESION QUE CONTIENE ESTEARATO DE MAGNESIO Y CELULOSA MICROCRISTALINA EN UN 2-20% EN PESO. DICHO COMPRIMIDO INDUCE FACILMENTE UN PROBLEMA EN LA COMPRESION AL PRENSAR EL COMPRIMIDO EN SU PRODUCCION
PE2008000219A 2007-02-01 2008-01-30 Comprimido que comprende 2-[[6-[(3r)-3-amino-1-piperidinil]-3,4-dihidro-3-metil-2,4-dioxo-1(2h)-pirimidinil]metil]-benzonitrilo y celulosa microcristalina PE20081734A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2007023584 2007-02-01

Publications (1)

Publication Number Publication Date
PE20081734A1 true PE20081734A1 (es) 2009-01-19

Family

ID=39156227

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2008000219A PE20081734A1 (es) 2007-02-01 2008-01-30 Comprimido que comprende 2-[[6-[(3r)-3-amino-1-piperidinil]-3,4-dihidro-3-metil-2,4-dioxo-1(2h)-pirimidinil]metil]-benzonitrilo y celulosa microcristalina

Country Status (11)

Country Link
US (1) US8697125B2 (es)
EP (1) EP2124901B1 (es)
JP (1) JP5284967B2 (es)
AR (1) AR065096A1 (es)
CA (1) CA2677193C (es)
CL (1) CL2008000280A1 (es)
ES (1) ES2639854T3 (es)
HR (1) HRP20171518T1 (es)
PE (1) PE20081734A1 (es)
TW (1) TW200836774A (es)
WO (1) WO2008093878A1 (es)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7407955B2 (en) 2002-08-21 2008-08-05 Boehringer Ingelheim Pharma Gmbh & Co., Kg 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
US7501426B2 (en) 2004-02-18 2009-03-10 Boehringer Ingelheim International Gmbh 8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions
DE102004054054A1 (de) 2004-11-05 2006-05-11 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine
CN113952338A (zh) 2005-02-03 2022-01-21 综合医院公司 治疗吉非替尼耐药性癌症的方法
DE102005035891A1 (de) 2005-07-30 2007-02-08 Boehringer Ingelheim Pharma Gmbh & Co. Kg 8-(3-Amino-piperidin-1-yl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel
CN103110948A (zh) 2005-11-04 2013-05-22 惠氏公司 mTOR抑制剂、赫赛汀和/或HKI-272的抗肿瘤组合
EP1852108A1 (en) 2006-05-04 2007-11-07 Boehringer Ingelheim Pharma GmbH & Co.KG DPP IV inhibitor formulations
PE20080251A1 (es) 2006-05-04 2008-04-25 Boehringer Ingelheim Int Usos de inhibidores de dpp iv
MX2008014024A (es) 2006-05-04 2008-11-14 Boehringer Ingelheim Int Formas poliformas.
CA2680684A1 (en) * 2007-03-13 2008-09-25 Takeda Pharmaceutical Company Limited Solid preparation comprising 2-[[6-[(3r)-3-amino-1-piperidinyl]-3,4-dihydro-3-methyl-2,4-dioxo-1 (2h)-pyrimidinyl]methyl]-4-fluorobenzonitrile
UA98799C2 (ru) * 2007-07-19 2012-06-25 Такеда Фармасьютикал Компани Лимитед Твердый препарат, включающий алоглиптин и гидрохлорид метформина
CL2008002427A1 (es) 2007-08-16 2009-09-11 Boehringer Ingelheim Int Composicion farmaceutica que comprende 1-cloro-4-(b-d-glucopiranos-1-il)-2-[4-((s)-tetrahidrofurano-3-iloxi)bencil]-benceno combinado con 1-[(4-metilquinazolin-2-il)metil]-3-metil-7-(2-butin-1-il)-8-(3-(r)-aminopiperidin-1-il)xantina; y su uso para tratar diabetes mellitus tipo 2.
US8022216B2 (en) 2007-10-17 2011-09-20 Wyeth Llc Maleate salts of (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide and crystalline forms thereof
PE20091730A1 (es) 2008-04-03 2009-12-10 Boehringer Ingelheim Int Formulaciones que comprenden un inhibidor de dpp4
EP3135285B1 (en) 2008-06-17 2018-08-15 Wyeth LLC Antineoplastic combinations containing hki-272 and vinorelbine
CN105963313A (zh) 2008-08-04 2016-09-28 惠氏有限责任公司 4-苯胺基-3-氰基喹啉和卡培他滨的抗肿瘤组合
KR20200118243A (ko) 2008-08-06 2020-10-14 베링거 인겔하임 인터내셔날 게엠베하 메트포르민 요법이 부적합한 환자에서의 당뇨병 치료
UY32030A (es) 2008-08-06 2010-03-26 Boehringer Ingelheim Int "tratamiento para diabetes en pacientes inapropiados para terapia con metformina"
JP2012502081A (ja) 2008-09-10 2012-01-26 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 糖尿病及び関連症状の治療のための組み合わせ治療
US20200155558A1 (en) 2018-11-20 2020-05-21 Boehringer Ingelheim International Gmbh Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug
RU2572529C2 (ru) * 2008-12-23 2016-01-20 Сандоз Аг Кристаллическая форма органического соединения
CN102256976A (zh) 2008-12-23 2011-11-23 贝林格尔.英格海姆国际有限公司 有机化合物的盐形式
TW201036975A (en) 2009-01-07 2010-10-16 Boehringer Ingelheim Int Treatment for diabetes in patients with inadequate glycemic control despite metformin therapy
CN102387795A (zh) * 2009-02-13 2012-03-21 贝林格尔.英格海姆国际有限公司 包含dpp-4抑制剂(利拉列汀)任选地组合其它抗糖尿病药的抗糖尿病药物
JP5685550B2 (ja) 2009-02-13 2015-03-18 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｓｇｌｔ２阻害剤、ｄｐｐ−ｉｖ阻害剤、更に必要により抗糖尿病薬を含む医薬組成物及びその使用
KR20190128004A (ko) 2009-04-06 2019-11-13 와이어쓰 엘엘씨 네라티닙을 이용한 유방암의 치료법
JP5732394B2 (ja) * 2009-07-28 2015-06-10 武田薬品工業株式会社 錠剤
EP3566697B1 (en) * 2009-11-09 2024-09-11 Wyeth LLC Tablet formulations of neratinib maleate
CN107115530A (zh) 2009-11-27 2017-09-01 勃林格殷格翰国际有限公司 基因型糖尿病患者利用dpp‑iv抑制剂例如利拉利汀的治疗
JP5775463B2 (ja) * 2009-12-18 2015-09-09 田辺三菱製薬株式会社 溶出安定性製剤
GEP20166487B (en) * 2010-04-30 2016-06-10 Takeda Pharmaceutical Enteric tablet
CA2797310C (en) 2010-05-05 2020-03-31 Boehringer Ingelheim International Gmbh Glp-1 receptor agonist and dpp-4 inhibitor combination therapy
EP3124041A1 (en) 2010-06-24 2017-02-01 Boehringer Ingelheim International GmbH Diabetes therapy
AR083878A1 (es) 2010-11-15 2013-03-27 Boehringer Ingelheim Int Terapia antidiabetica vasoprotectora y cardioprotectora, linagliptina, metodo de tratamiento
UY33937A (es) 2011-03-07 2012-09-28 Boehringer Ingelheim Int Composiciones farmacéuticas que contienen inhibidores de dpp-4 y/o sglt-2 y metformina
JP5874545B2 (ja) * 2011-06-20 2016-03-02 アステラス製薬株式会社 経口投与用医薬組成物
HUE061596T2 (hu) 2011-07-15 2023-07-28 Boehringer Ingelheim Int Szubsztituált dimer kinazolin származék, annak elõállítása és alkalmazása az I. és II. típusú cukorbetegség kezelésére szolgáló gyógyszerkészítményekben
US9555001B2 (en) 2012-03-07 2017-01-31 Boehringer Ingelheim International Gmbh Pharmaceutical composition and uses thereof
EP3685839A1 (en) 2012-05-14 2020-07-29 Boehringer Ingelheim International GmbH Linagliptin for use in the treatment of albuminuria and kidney related diseases
EP4151218A1 (en) 2012-05-14 2023-03-22 Boehringer Ingelheim International GmbH Linagliptin, a xanthine derivative as dpp-4 inhibitor, for use in the treatment of sirs and/or sepsis
WO2013174767A1 (en) 2012-05-24 2013-11-28 Boehringer Ingelheim International Gmbh A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference
JP6309895B2 (ja) * 2012-09-27 2018-04-11 株式会社三和化学研究所 アナグリプチン含有製剤
CN103877054B (zh) * 2012-12-21 2016-05-25 北大方正集团有限公司 一种苯甲酸阿格列汀片剂及其制备方法
CN103610661B (zh) * 2013-11-22 2017-09-12 威海迪素制药有限公司 一种组合物
CN104721188A (zh) * 2013-12-20 2015-06-24 中美华世通生物医药科技（武汉）有限公司 一种稳定的含苯甲酸阿格列汀的组合物
JP6238921B2 (ja) * 2014-02-17 2017-11-29 大原薬品工業株式会社 イルベサルタンを含有する錠剤
WO2015128453A1 (en) 2014-02-28 2015-09-03 Boehringer Ingelheim International Gmbh Medical use of a dpp-4 inhibitor
WO2016202961A1 (en) 2015-06-17 2016-12-22 H E X A L Aktiengesellschaft Alogliptin formulation
US10155000B2 (en) 2016-06-10 2018-12-18 Boehringer Ingelheim International Gmbh Medical use of pharmaceutical combination or composition
JP7250305B2 (ja) * 2018-10-02 2023-04-03 共和薬品工業株式会社 メマンチン又はその薬物学的に許容される塩を含む医薬組成物及びその製造方法
JP7340572B2 (ja) * 2021-08-20 2023-09-07 セトラスホールディングス株式会社 酸化マグネシウム錠剤

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5200193A (en) * 1987-04-22 1993-04-06 Mcneilab, Inc. Pharmaceutical sustained release matrix and process
JP3836528B2 (ja) 1995-11-17 2006-10-25 エスエス製薬株式会社 イブプロフェン含有錠剤及びその製造法
JP4185974B2 (ja) 1996-05-20 2008-11-26 ジー． デイー． サール、 リミテッド、 ライアビリティ、 カンパニー カリウム、ナトリウムおよびトリスオキサプロジン塩医薬組成物
US6348216B1 (en) * 1996-06-10 2002-02-19 Knoll Pharmaceutical Company Ibuprofen and narcotic analgesic compositions
JPH1059842A (ja) 1996-08-13 1998-03-03 Lion Corp 錠剤用組成物及び打錠方法
AR016827A1 (es) 1997-08-22 2001-08-01 Smithkline Beecham Corp PROCEDIMIENTO PARA LA PREPARACIoN DE UNA TABLETA FARMACÉUTICA
UA60335C2 (uk) * 1997-08-26 2003-10-15 Хехст Маріон Рассел, Інк. Фармацевтична композиція, яка об'єднує піперидиноалканол з протинабряковим агентом
UA74141C2 (uk) 1998-12-09 2005-11-15 Дж.Д. Сірл Енд Ко. Фармацевтична композиція на основі тонкоподрібненого еплеренону (варіанти), спосіб її одержання та спосіб лікування розладів, опосередкованих альдостероном (варіанти)
KR100645866B1 (ko) * 1999-12-08 2006-11-15 파마시아 코포레이션 발데콕시브 조성물
AR029538A1 (es) * 2000-07-06 2003-07-02 Wyeth Corp Composiciones farmaceuticas de agentes estrogenicos
JP2002179559A (ja) 2000-10-06 2002-06-26 Takeda Chem Ind Ltd 薄層糖衣錠およびその製造方法
US6645526B2 (en) * 2001-11-13 2003-11-11 Mylan Pharmaceuticals, Inc. Storage stable thyroxine active drug formulations and methods for their production
JP2004189653A (ja) 2002-12-10 2004-07-08 Yoshio Itabashi イブプロフェン含有錠剤
US20040214804A1 (en) * 2003-04-25 2004-10-28 Pharmacia Corporation Combination of an aldosterone receptor antagonist and an anti-obesity agent
RU2766487C2 (ru) * 2004-01-20 2022-03-15 Новартис Аг Композиция и способ прямого прессования
CN102079743B (zh) * 2004-03-15 2020-08-25 武田药品工业株式会社 二肽基肽酶抑制剂
DE202006000591U1 (de) 2005-01-20 2006-03-30 Analyze & Realize Ag Gelenkformulierung
EP1906936A2 (en) 2005-05-18 2008-04-09 Combino Pharm, S.L. Formulations containing losartan and/or its salts
EP1931350B2 (en) * 2005-09-14 2021-08-04 Takeda Pharmaceutical Company Limited Administration of dipeptidyl peptidase inhibitors
TW200745079A (en) * 2005-09-16 2007-12-16 Takeda Pharmaceuticals Co Polymorphs of benzoate salt of 2-[[6-[(3R)-3-amino-1-piperidinyl]-3,4-dihydro-3-methyl-2,4-dioxo-1(2H)-pyrimidinyl]methyl]-benzonitrile and methods of use therefor
WO2007078726A2 (en) * 2005-12-16 2007-07-12 Merck & Co., Inc. Pharmaceutical compositions of combinations of dipeptidyl peptidase-4 inhibitors with metformin

Also Published As

Publication number Publication date
EP2124901B1 (en) 2017-07-19
AR065096A1 (es) 2009-05-13
ES2639854T3 (es) 2017-10-30
WO2008093878A1 (en) 2008-08-07
JP2010517936A (ja) 2010-05-27
JP5284967B2 (ja) 2013-09-11
CA2677193A1 (en) 2008-08-07
CA2677193C (en) 2015-06-30
TW200836774A (en) 2008-09-16
US20090318482A1 (en) 2009-12-24
HRP20171518T1 (hr) 2017-11-17
EP2124901A1 (en) 2009-12-02
US8697125B2 (en) 2014-04-15
CL2008000280A1 (es) 2008-08-18

Similar Documents

Publication Publication Date Title
PE20081734A1 (es) Comprimido que comprende 2-[[6-[(3r)-3-amino-1-piperidinil]-3,4-dihidro-3-metil-2,4-dioxo-1(2h)-pirimidinil]metil]-benzonitrilo y celulosa microcristalina
GB0906579D0 (en) Pharmaceuticals, compositions and methods of making and using the same
PE20140923A1 (es) Preparacion solida que comprende alogliptina y clorhidrato de metformina
ATE469895T1 (de) Cgrp-rezeptorantagonisten
CA119744S (en) Bottle
MX2009005363A (es) Pirimidinas y su uso como antagonistas del receptor cxcr2.
MX2012007340A (es) Anticuerpos anti/her3 y usos de los mismos.
ATE496051T1 (de) Pyrazolotetrahydropyridinderivate als orexinrezeptorantagonisten
EP1971366A4 (en) Human anti-IL-23 antibodies, compositions, methods and uses
ATE480524T1 (de) Pyridazinonderivate als schilddrüsenhormon- rezeptoragonisten
IL195218A0 (en) 2,4-diamino pyrimidines as cell cycle kinase inhibitors
ZA200700084B (en) 2,4-DI(aminopheyl) pyrimidines AS PKL inhibitors
EA201100306A1 (ru) Производные циклогексиламида и их применение в качестве антагонистов рецептора crf-1
NO20090203L (no) IL-8 receptorantagonist
MY145644A (en) 5,6-bisaryl-2-pyridine-carboxamide derivatives, preparation and application thereof in therapeutics as urotensin ii receptor antagonists
CO6612226A2 (es) Tableta
CL2008003266A1 (es) Compuestos derivados de pirimidindiona y triazindiona sustituidas con cicloguanidina, utiles como antagonista del receptor de procineticina; composicion farmaceutica que comprende dichos compuestos; y uso en el tratamiento de enfermedades gastrointestinales.
PL1987357T3 (pl) Polipeptydy rozpoznawane przez przeciwciała anty-Trichinella oraz ich zastosowanie
TR201909067T4 (tr) Bir sağım başlığı.
ECSP099673A (es) Formas sólidas de un inhibidor de cinasa raf
EA200601759A1 (ru) Композиции рамиприла
EP1844381A4 (en) RAW CHARGER STANDARD CMOS CONTROLLER WITH LOW WASTE VOLTAGE, HIGH PSRR AND NEW DYNAMIC COMPENSATION
AR092843A1 (es) Preparacion solida
WO2011022467A3 (en) Controlled-release formulations of anabaseine compounds and uses thereof
PL122635U1 (pl) Pisak ekranowy, zwłaszcza do tabletu

Legal Events

Date Code Title Description
FA Abandonment or withdrawal